in VIVO: a new delivery platform for ... - Fight Prostate Ca...

Fight Prostate Cancer

2,956 members1,313 posts

in VIVO: a new delivery platform for prostate cancer chemotherapy

Maxone73 profile image
0 Replies

As you know, we have an abundance of "stuff" that can kill cancer cells in a bucketload of ways (please note the scientific terms I used :-P ) but we need ways to target only cancer cells to make treatments a breeze on our body

sciencedirect.com/science/a...

Why is 4armPEG-DD a good candidate to help us?

● Targeted Delivery: 4armPEG-DD is designed to specifically target PSMA-positive prostate cancer cells. PSMA is overexpressed in 80-90% of prostate cancers, making it a suitable target for therapy. This targeted approach is expected to increase the drug's effectiveness while minimizing its impact on healthy cells.

● Enhanced Permeability and Retention (EPR) Effect: The nano-size of 4armPEG-DD (approximately 110 nm) allows it to take advantage of the EPR effect. This means that the nanoprodrug can preferentially accumulate in tumor tissues due to the leaky vasculature and impaired lymphatic drainage often found in tumors.

● Controlled Release: The disulfide bond linking docetaxel to the 4-arm PEG is sensitive to the reducing environment inside tumor cells. This ensures that docetaxel is released primarily within the cancer cells, reducing systemic toxicity.

● Biocompatibility: The use of PEG as the carrier material contributes to the safety of the nanoprodrug. PEG is biocompatible and has a long history of safe use in clinical settings. This reduces the risk of adverse reactions and improves the overall tolerability of the treatment.

The fact that it has a long history of use in clinical settings could also shorten the clinical trials!

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy

New paper below [1]. {MAOA has been a promising therapy for 20 years imo.} "Previous studies have...
pjoshea13 profile image

Phase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer

Doctors in Perth, Australia are leading a Phase 3 clinical trial called ProstACT GLOBAL, which is...
Maxone73 profile image

Developments in the Continued Search for a Prostate Cancer Vaccine...

Greetings FPC members, As some of you know, I believe that the development of a vaccine or vaccines...
NPfisherman profile image

Understanding the Abscopal Effect and its Potential Role in Developing a Cure for Cancer-Part 2-Possible Ways to Ensure the Abscopal Effect

In my introduction on the abscopal effect, we left off with the concepts of ensuring the effect and...
NPfisherman profile image

Androgen Receptor Signalling Inhibitors – Post-Chemotherapy, Pre-Chemotherapy and now in castration sensitive prostate cancer - ERC -6.15.21

Androgen Receptor Signalling Inhibitors – Post-Chemotherapy, Pre-Chemotherapy and now in...
cujoe profile image